1. Introduction {#sec1}
===============

Highly active combination antiretroviral therapy (cART) has significantly improved survival and reduced the rates of AIDS-related complications among HIV-infected persons \[[@B1]--[@B3]\]. Emergence of HIV variants with reduced susceptibility to antiretroviral (ARV) medications can significantly limit the effectiveness and durability of treatment \[[@B3]--[@B8]\]. Use of ARV resistance testing to optimize cART selection has been associated with better virologic and clinical outcomes \[[@B9]--[@B11]\] and improved survival \[[@B12]\], and resistance testing is now generally recommended in the clinical management of HIV infection \[[@B13]--[@B15]\]. We have previously shown that use of genotypic and phenotypic testing increased in the HIV Outpatient Study (HOPS) during 1999--2006 and that the likelihood of testing varied by HIV disease severity and demographic characteristics \[[@B16]\].

Recent European and Canadian studies have suggested that both the prevalence \[[@B17], [@B18]\] and incidence \[[@B19], [@B20]\] of ARV resistance among HIV-infected persons have declined, due predominately to a decrease in the proportion of patients with pre-cART mono- or dual-ARV experience, and the increasing use and effectiveness of more tolerable and potent cART regimens that appear less likely to result in resistance mutations \[[@B18]--[@B22]\]. However, relatively few recent data on prevalence or incidence of ARV resistance mutations are available from US patient populations \[[@B7], [@B23]--[@B25]\]. We sought to assess frequencies and trends in ARV resistance among HIV strains isolated from a demographically diverse cohort of ARV-experienced US patients who underwent genotypic testing (GT) as part of routine care between 1999 and 2008.

2. Methods {#sec2}
==========

2.1. The HIV Outpatient Study {#sec2.1}
-----------------------------

The HIV Outpatient Study (HOPS) is an ongoing, longitudinal cohort study of HIV-infected patients in care followed at HIV specialty clinics in the US since 1993. The HOPS methodology has been described previously \[[@B26]\]. In brief, trained staff abstract patient data, including sociodemographic characteristics, diagnoses, treatments, and laboratory values (including results of antiretroviral resistance testing), from medical records and enter them into an electronic database for central processing and analysis. HIV drug resistance testing is performed at the discretion of the clinician provider. The institutional research review boards of the Centers for Disease Control and the local participating sites have approved and reviewed the ethical conduct of this study yearly.

2.2. Study Population {#sec2.2}
---------------------

For this analysis, we examined data from active participants seen at 10 HOPS clinics between January 1, 1999, and December 31, 2008, using the HOPS dataset as of September 30, 2009. Participants were considered active if they had at least two HOPS-related encounters documented (i.e., clinic visits, hospitalizations, and laboratory measurements but not telephone calls), and at least one of these encounters occurred during the calendar years of interest. The study population was restricted to patients who underwent GT while receiving ARV therapy with a documented plasma HIV RNA viral load \>1,000 copies/mL; we chose the measurement most proximal to the date of GT within the six months prior and two weeks after the GT during 1999--2008. Only GT results documented on or after the first HOPS visit were considered; GT results indicating insufficient virus or inadequate specimen were excluded from the analyses.

2.3. Variable Definitions {#sec2.3}
-------------------------

"Mono-dual NRTI exposure" was defined as any prior treatment with a regimen containing only one or two NRTIs as of the last eligible genotypic test in the year of interest. "Triple-class exposure" (TCE) was defined as four continuous months of exposure to ARVs from each of the three main classes (i.e., NRTIs, NNRTIs, and PIs) as of the last eligible genotypic test in the year of interest; resistance to other novel drug classes was not evaluated. "Only cART exposure" was defined as having never been prescribed non-cART (i.e., mono-dual NRTI) regimens as of the last eligible genotypic test in the year of interest. "Triple-class resistance" (TCR) was defined as the presence or presumed accumulation (i.e., any prior documentation) of mutations to ARVs from each of the three main classes.

2.4. Analysis Methods {#sec2.4}
---------------------

Using the International AIDS Society (IAS) December 2008 listing of clinically relevant mutations, we assessed the frequency of major HIV resistance mutations in viruses isolated from patients who were followed in HOPS during 1999--2008 and underwent at least one eligible genotype test during that period. For patients who had multiple genotypic tests per year, we focused on the last test. Annual frequencies of ARV resistance were calculated as the number of patients with genotype(s) that during a calendar year demonstrated resistance, or had previously demonstrated resistance (numerator), divided by the number of patients with an eligible genotype performed in that year (denominator) and expressed as a percentage. Thus, resistance was determined by the presence of either a current or previously detected mutation(s) among patients tested that year, even if a previously detected mutation(s) was no longer apparent on the most recent resistance assay. We examined resistance to each of the three main drug classes (NRTIs, NNRTIs, and PIs) among all ARV-treated patients and among patients known to have been specifically exposed to agents in these drug classes. We also examined the frequency of TCR among TCE patients. Because M184V is a frequently observed mutation that develops rapidly after exposure to lamivudine and emtricitabine, but which does not confer resistance to all NRTIs, we conducted alternate analyses excluding this mutation. Finally, we assessed the likely impact of excluding genotypic tests performed at HIV RNA viral load ≤1,000 copies/mL on our findings, by examining frequency of insufficient specimens and resistance patterns in this subset.

Resistance was assessed as of the last eligible genotypic test in the year of interest. Trends in patient characteristics and in mutation frequency were evaluated using general linear models (PROC GLM), reporting *P* values over the 10-year period of the study. All analyses were performed using SAS version 9.1 (Cary, NC). Statistical associations with *P* values \<0.05 were considered significant.

3. Results {#sec3}
==========

3.1. Temporal Trends in Genotypic Resistance Testing {#sec3.1}
----------------------------------------------------

The 6,158 HOPS patients under observation during 1999--2008 had a total of 3,305 GT results during this period. We identified 1,867 (56%) genotypic tests performed while the patients were prescribed ARVs, of which 1,570 (84%) were performed when the most proximal HIV RNA was \>1,000 copies/mL. These 1,570 GT results were obtained from a total of 906 patients, of whom 541 patients contributed one eligible GT result, 206 contributed two results, and 159 contributed ≥3 results. Taking the last GT result per patient per year resulted in 1,436 GT assessments for 906 unique patients being available for resistance trend analyses during 1999--2008.

Notably, while the annual number of active HOPS participants receiving ARVs in the HOPS oscillated around 2,700 during 1999--2008, the annual number and relative proportion of participants receiving ARVs who had at least one documented episode of viremia (HIV RNA \>1,000 copies/mL) decreased markedly from nearly 1,400 to fewer than 500 participants (*P* \< 0.0001, [Figure 1](#fig1){ref-type="fig"}). Correspondingly, since 2003, the number of persons who were eligible for GT and met inclusion criteria for our analyses decreased steadily (from 240 persons in 2003 to 63 persons in 2008, *P* \< 0.0001). Furthermore, the percentage of genotypic tests performed among ARV-treated patients whose HIV RNA was ≤1,000 copies/mL (i.e., genotypic tests that we excluded from the present analyses) increased over time (4.5% in 1999 (6/133) versus 18.2% (16/88) in 2008, *P* = 0.008). See [Section 3.5](#sec3.5){ref-type="sec"} for supplemental results for excluded patients with HIV RNA ≤1,000 copies/mL.

3.2. Characteristics of Patients with Genotypic Tests Performed {#sec3.2}
---------------------------------------------------------------

Of the 906 patients analyzed, the median age was 43 years, 77% were male, 37% were non-Hispanic black, 14% were Hispanic or other or unknown race/ethnicity, 54% were men who had sex with men (MSM), 11% were injection drug users at the time of HIV diagnosis, and 29% were heterosexuals ([Table 1](#tab1){ref-type="table"}). As of their last eligible genotypic test, 49% had public insurance, 38% had a CD4+ cell count \<200 cells/mm^3^, 80% had been diagnosed with AIDS by immunologic or clinical criteria, and the median HIV RNA was 4.3 log~10~ copies/mL at last eligible genotypic test. In crude analyses, the patients who underwent GT during 1999--2008 were increasingly more likely over time (test for trend, *P* \< 0.05) to be older, female, of non-Hispanic black race/ethnicity, to have reported heterosexual risk for HIV infection, and to have been publicly insured ([Table 1](#tab1){ref-type="table"}). The median CD4+ cell count appeared higher, and the HIV viral load appeared lower among patients who underwent GT in the middle of the study period (i.e., year 2004) compared with the start and the end of the period, without statistically significant trends over time ([Table 1](#tab1){ref-type="table"}).

3.3. Temporal Trends in ARV Exposures {#sec3.3}
-------------------------------------

From 1999 to 2008, among patients who underwent GT each year, the annual percentage of patients with prior NNRTI exposure increased (66% to 75%, test for linear trend, *P* = 0.012), while the percentage with any prior PI exposure remained stable (89% to 87%, *P* = 0.89) and the percentage with ritonavir-boosted PI exposure increased markedly (6% to 81%, *P* \< 0.001) ([Figure 2](#fig2){ref-type="fig"}). The annual percentages with mono-dual NRTI exposure decreased (75% to 52%, *P* \< 0.001), while the fraction of cART-only exposed participants increased (19% to 38%, *P* \< 0.001), and the fraction of participants with TCE remained unchanged (47% to 51%, *P* = 0.11) ([Figure 3](#fig3){ref-type="fig"}).

3.4. Temporal Trends in Frequency of Genotypic Resistance {#sec3.4}
---------------------------------------------------------

During 1999 to 2008, the annual frequency of any resistance mutations decreased for all patients tested (88% to 79%, test for linear trend *P* = 0.054) and for persons with mono-dual NRTI exposure (93% to 88%, *P* = 0.066) but not among persons who were exposed only to cART (68% to 63%, *P* = 0.32) or who had TCE (95% versus 94%, *P* = 0.43) ([Table 2](#tab2){ref-type="table"}, part A). Although the differences were not statically significant, as evidenced by overlapping 95% CIs, the annual frequencies of resistance tended to be lower, among cART-only exposed patients compared with mono- and dual-NRTI-exposed patients or patients with TCE ([Table 2](#tab2){ref-type="table"}, part A).

Among all patients receiving genotypic tests, regardless of their ARV regimen exposures, the frequency of any major resistance mutations (88% to 79%) ([Table 2](#tab2){ref-type="table"}, part A top line) as well as NRTI mutations (82% to 67%) and PI mutations (65% to 41%) tended to decrease over time, but only the decline in PI resistance was statistically significant ([Table 2](#tab2){ref-type="table"}, part B). The resistance findings were observed in the context of an increasing duration of cumulative months of exposure to all major classes of ARVs among the patients we studied ([Table 1](#tab1){ref-type="table"}).

In analyses restricted to subsets of patients exposed to the relevant ARV drug classes, the frequencies of resistance to NRTIs (82% to 67%, test for linear trend *P* = 0.094) among NRTI-exposed patients and to NNRTIs (71% to 68%, *P* = 0.38) among NNRTI-exposed did not decrease significantly, but the frequency of resistance to PIs (71% to 46%, *P* = 0.010) among PI-exposed did ([Table 2](#tab2){ref-type="table"}, part C; [Figure 4](#fig4){ref-type="fig"}). The annual frequency of TCR among patients with TCE also did not decrease significantly (66% to 41%, *P* = 0.094) ([Figure 4](#fig4){ref-type="fig"}).

In the sensitivity analyses that excluded the M184V mutation in reverse transcriptase, the frequency of NRTI resistance was 10--15% lower in each given calendar year, but the frequency of TCR decreased by \<5% in each year (data not shown). Furthermore, when we restricted analyses to the first or the last genotypic test per patient during 1999--2008, to avoid correlated outcomes in the analyses, the declines in resistance observed in the primary analyses persisted.

The decrease in prevalence of PI resistance, both within the entire cohort and among persons exposed to PIs, correlated with a shift in exposures to specific PIs. The most common current or prior PI exposures in 1999 were to nelfinavir (70%), indinavir (69%), saquinavir (66%), and full-dose ritonavir (51%), whereas by 2008, the most common PI exposures were to low-dose ritonavir for PI boosting (75%), lopinavir (65%), atazanavir (53%), and indinavir (40%). Furthermore, we did not see a trend whereby exposure to PIs (as a class) was increasingly distanced from the date of genotype (i.e., differential risk for reversion to wild-type virus). In each calendar year, among patients who had any PI exposure to date, over 75% underwent GT while being prescribed at least one PI agent.

3.5. ARV Resistance according to HIV RNA Level {#sec3.5}
----------------------------------------------

In supplemental analyses, we compared the frequency (non-cumulative) of resistance mutations detected in each patient\'s most recent viral isolate from 2004--2008, according to HIV RNA level at GT, contrasting results for patients whom we included (HIV RNA \>1,000 copies/mL) and excluded (HIV RNA ≤1,000 copies/mL) in our primary analyses. Of 624 unique patients who had their last GT while on ARVs in that period, 42 (7%), and 143 (23%) patients, respectively, had GT performed with the closest HIV RNA in the range of 500--1,000 copies/mL and \<500 copies/mL. The percentages of patients missing GT results because of "insufficient specimen" were 2%, 12%, and 46% in samples with HIV RNA \>1,000 copies/mL, 500--1,000 copies/mL, and \<500 copies/mL, respectively. In the remaining evaluable isolates, the frequency of any major IAS resistance mutation was 76%, 76%, and 47% for the three HIV RNA strata, respectively.

4. Discussion {#sec4}
=============

As treatment options for HIV-infected patients have improved over time in terms of greater effectiveness, tolerability, and sheer number of available antiretrovirals, we found that a decreasing proportion of ARV-treated patients in our diverse US-based cohort had viremia and thus were candidates for GT to optimize cART ([Figure 1](#fig1){ref-type="fig"}). Among ARV-experienced patients in our cohort who underwent GT in the context of routine outpatient HIV care during 1999--2008, viruses harboring resistance mutations to the main ARV classes were detected with either a constant or possibly decreasing frequency over time; resistance mutations to protease inhibitors decreased significantly in viral strains of patients who had ever been exposed to PIs.

The magnitude and temporal trends in the frequency of resistance mutations among HIV strains isolated from patients who undergo GT can be influenced by a myriad of factors, including but not necessarily limited to (i) changes in the sociodemographic and clinical characteristics of the patient population over time, particularly in a dynamic cohort such as the HOPS in which patients can enter or leave care; (ii) changes in the nature and extent of ARV exposure over time (e.g., decreasing exposure to mono- or dual-NRTI regimens, increasing exposure to newer more potent and tolerable cART regimens as first-line or salvage therapy); (iii) more widespread utilization of GT and changes in the characteristics of patients considered appropriate candidates for such testing; (iv) archiving of mutations in the absence of selective antiretroviral drug pressures; (v) cohort-level changes in the degree of patient adherence to prescribed ARVs and the related likelihood of experiencing viremia while prescribed cART.

It is important to note that our findings regarding the extent of and trends in the frequency of ARV resistance mutations apply only to the decreasing annual proportion of HOPS patients eligible for resistance testing \[[@B16]\], that is, persons who experienced viremia while receiving cART. Our aim was to describe what clinicians may see in practice when testing ARV-experienced patients. Modeling of population-wide prevalence of resistance in the HOPS cohort (including both viremic and virologically suppressed patients on cART), which was not undertaken here but has been attempted in other populations \[[@B25], [@B27]\], would presumably reveal lower prevalence of resistance cohort-wide and potentially different trends over time. Such modeling approaches typically require strong assumptions about the likelihood of archived resistance mutations among patients who are currently virologically suppressed and imputations of missing data for many ARV-experienced patients who did not undergo GT (the bulk of ARV-experienced patients in the HOPS, per [Figure 1](#fig1){ref-type="fig"}) but can provide useful comparative data in large samples under different assumed scenarios.

Although we did not detect statistically significant declines in the frequency of any ARV resistance among HIV strains from all HOPS patients who underwent GT in clinical practice and among the subset who were solely cART-experienced, recent population-based studies provide supporting evidence for such declines. These studies suggest that the incidence of ARV resistance is decreasing \[[@B19], [@B20]\] due to increasing use of cART regimens that are more tolerable, potent, easier to adhere to, and consequently less likely to result in resistance \[[@B18], [@B21], [@B22]\] and due to smaller proportions of patients failing antiretroviral therapy \[[@B7], [@B19]\] or being sufficiently viremic while receiving cART to allow for the performance of GT.

We also found that HOPS patients who underwent GT were increasingly less likely to have virus with PI resistance, whereas potential declines in NNRTI resistance were more modest and nonsignificant over time. These trends might reflect shorter persistence of PI mutations than NNRTI mutations in the absence of drug pressure or greater use of ritonavir-boosted PIs, which are more potent and confer greater barriers to the emergence of resistance. Among ARV-naïve patients initiating cART who were followed in British Columbia, Canada, the development of ARV drug resistance was associated with the use of non-boosted PI-based or NNRTI-based regimens \[[@B18]\], suboptimal levels of ARV adherence (particularly in the 80%--95% range), low pre-cART CD4+ cell counts, and high baseline HIV RNA levels \[[@B18], [@B28]\], and was reduced for patients who initiated cART in 2002--2004 versus earlier \[[@B18]\]. In the Swiss Cohort study, the estimated prevalence of resistance in a population of over 8,000 ARV-exposed patients also decreased by approximately 12% during 1999 to 2007 and was driven by loss to follow up or death of patients with mono-dual NRTI exposure countered by continued enrollment of patients starting cART with NNRTI-based or boosted PI-based regimens \[[@B17]\].

We excluded from our primary analyses genotypic tests performed on plasma HIV RNA samples with ≤1,000 copies/mL because such assays may provide unreliable results (i.e., appear falsely negative for resistance mutations) due to insufficient HIV RNA copy and such patients may have low level self-limited viremia (viral "blips") rather than true virologic failure. Indeed, when comparing results from genotypic tests performed when HIV RNA \>1,000 copies/mL versus ≤1,000 copies/mL in the latest years of the study, we found that the frequency of "insufficient specimens" was higher, while the frequency of detected resistance was lower in the latter group, especially when HIV RNA \<500 copies/mL. Aside from concern for bias due to nonevaluable samples, including the relatively few results from genotypic tests performed with HIV RNA between 500 and 1,000 copies/mL would have likely accentuated the observed decreases in the frequencies of resistance at GT through 2008. Our analytic approach ensured more comparable data over time, and the declines in resistance we observed are likely conservative.

Our findings suggestive of declines over time in rates of ARV resistance are notable for at least two reasons. First, because of the method we employed to analyze cumulative frequency of ARV resistance to date, by "carrying forward" previously identified mutations that may have become archived, the frequency of resistance in later years should tend to be higher (because patients have had the opportunity to accumulate more mutations over time as revealed by successive genotypic tests performed) than would be suggested if results were based on a single genotypic test that year. Further, one might expect to find higher overall frequency of mutations over time, as newer ARVs are added to the three drug classes, with new, often ARV-specific, resistance mutations being identified and detected using contemporary genotypic tests.

We believe that three factors most likely explain the lower frequency of resistance among HOPS patients who underwent GT over time: (i) the increasing use of more tolerable and potent cART regimens associated with higher barriers to resistance or more complex mutational pathways necessary for resistance to develop; (ii) the decreasing proportion of HOPS patients under observation having mono-dual NRTI exposure; (iii) the increasing and more widespread use of GT in the HOPS with possible testing of patients at lower risk of virologic failure due to resistance. The decreasing frequency of resistance to PIs in our population was associated with increased use of more potent PIs (i.e., ritonavir boosting). This trend could have also occurred if exposures to PIs were increasingly distant, which would have allowed greater opportunity for PI resistance mutations to become archived before patients underwent GT. However, we found no evidence that the time between PI exposure among exposed patients and time of genotypic test differed over the study observation period.

In a cohort study of 1,587 HIV-infected patients at the University of North Carolina (2000--2006), of whom 607 had at least one genotype, there were 27.2% of patients with TCR among 437 patients who had GT and any exposure to each of the three drug classes. This was lower than the 40.6% estimated for patients with TCE in our study, possibly because we required a minimum of three months of exposure on each of the three drug classes to define TCE \[[@B25]\]. Our findings of high frequency of any resistance mutations in the genotyped population are consistent with the findings from an early large genotypic substudy of patients with HIV viral load \>500 copies/mL in the population-based HIV Cost and Service Utilization Study (HCSUS), which documented that 76% of tested patients had evidence of genotypic resistance to one or more antiretroviral drugs in 1996--1998 \[[@B23]\].

The findings from our ecological analyses should be interpreted in light of several additional caveats and limitations. First, most patients receiving antiretrovirals in the HOPS were virologically suppressed and, over time, fewer were eligible for GT during the study period, resulting in a progressively smaller and more select sample of patients with GT results, raising the concern for potential bias and limiting statistical power. Second, we relied on data collected in the course of regular HIV care since our purpose was to reflect what a treating clinician would see. Not all eligible patients had GT performed, and trends in and magnitude of resistance frequencies detected may have been different if all ARV-experienced, viremic patients had undergone scheduled GT at regular intervals \[[@B16]\]. Third, some mutations that arose during prior courses of ARV therapy (before the advent of GT or before HOPS entry) may have no longer been apparent because of a lack of continuing ARV drug pressure; however, we do not believe this effect would have systematically biased our findings over calendar years away from the null hypothesis. Fourth, patients who harbored the greatest number of mutations were also more likely to have had advanced HIV disease and an extensive ARV treatment history that involved mono-dual NRTI exposure (data not shown). These patients may have died or been lost to follow up at rates higher than other HOPS patients during the study period. Moreover, the demographics of patients who underwent GT shifted toward a higher percentage of women, persons of color, and those with heterosexual risk for HIV infection, all factors which are associated with more recent HIV diagnoses and less exposure to ART in the HOPS (data not shown). These dynamics may explain in part the decreasing trends in resistance in our open cohort. Finally, we have no systematic data on pre-ARV resistance profiles for the majority of patients and therefore could not evaluate the role of primary transmitted drug resistance or incidence rates of HIV resistance.

In conclusion, the frequency of ARV resistance mutations detected for HIV among patients in the HOPS who were tested in the course of routine clinical practice was high and tended to decrease during 1999--2008. The decreasing frequency of genotypic resistance corresponded with at least two trends: an increasing use of more tolerable and potent cART, including boosted PI regimens, and a decreasing proportion of HOPS patients with histories of exposure to mono- and dual-NRTI ARV regimens. Our findings support the continuing need for routine HIV resistance testing and monitoring of evolving ARV resistance patterns among ARV-treated patients \[[@B15]\] who experience virologic nonsuppression while on therapy. Available evidence suggests that adoption of such testing as routine would facilitate tailoring of more effective cART \[[@B29]\], reduce the likelihood of further resistance evolution, and ultimately augment cART-related reductions in HIV-related mortality \[[@B7], [@B8], [@B12]\].

The findings and conclusions in this paper are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.
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![Number of patients who underwent genotypic testing (GT) while prescribed antiretrovirals (ARVs) and viremic (HIV viral load \>1,000 copies/mL), the HIV Outpatient Study, 1999--2008.](ART2012-230290.001){#fig1}

![Frequency of antiretroviral exposures, according to ARV class, among viremic (HIV viral load \>1,000 copies/mL) patients who underwent genotypic testing in the HIV Outpatient Study, 1999--2008. Note: Any "PI exposed" included ritonavir-boosted and unboosted regimens. "PIB exposed" included only ritonavir-boosted regimens.](ART2012-230290.002){#fig2}

![Frequency of ART experience categories, among viremic (HIV viral load*\>*1,000 copies/mL) patients who underwent genotypic testing in the HIV Outpatient Study, 1999--2008.](ART2012-230290.003){#fig3}

![Frequency of genotypic resistance by class of antiretroviral, among exposed patients, in the HIV Outpatient Study, 1999--2008.](ART2012-230290.004){#fig4}

###### 

Characteristics of ARV-experienced patients who had genotypic testing performed at viral load \>1000 copies/mL and while on ARVs in selected calendar years, and overall, the HIV Outpatient Study, 1999--2008.

                                                                                                       1999                 2004                2008                Unique total^§^   
  ---------------------------------------------------------------------------------------------------- ------- ------------ ------ ------------ ------ ------------ ----------------- ------------
  Age, years^∗†^                                                                                                                                                                      
   Median (IQR)                                                                                        40      (36, 47)     43     (39, 48)     41     (38, 51)     43                (38, 49)
   \<35                                                                                                18      15.2         17     10.4         9      14.3         110               12.1
   35--49                                                                                              78      66.1         110    67.1         36     57.1         583               64.4
   50+                                                                                                 22      18.6         37     22.6         18     28.6         213               23.5
                                                                                                                                                                                      
  Gender^†^                                                                                                                                                                           
   Female                                                                                              25      21.2         36     22.0         24     38.1         208               23.0
   Male                                                                                                93      78.8         128    78.0         39     61.9         698               77.0
                                                                                                                                                                                      
  Race^†^                                                                                                                                                                             
   White                                                                                               73      61.9         75     45.7         22     34.9         448               49.4
   Black                                                                                               30      25.4         65     39.6         30     47.6         334               36.9
   Other/unknown                                                                                       15      12.7         24     14.6         11     17.5         124               13.7
                                                                                                                                                                                      
  HIV Risk^†^                                                                                                                                                                         
   Heterosexual                                                                                        31      26.3         53     32.3         27     42.9         266               29.4
   IDU                                                                                                 12      10.2         15     9.1          9      14.3         102               11.3
   MSM                                                                                                 70      59.3         85     51.8         23     36.5         487               53.8
   Other/unknown                                                                                       5       4.2          11     6.7          4      6.4          51                5.6
                                                                                                                                                                                      
  Insurance^∗†^                                                                                                                                                                       
   Private                                                                                             54      45.8         58     35.4         21     33.3         381               42.0
   Public                                                                                              49      41.5         93     56.7         37     58.7         444               49.0
   Other/unknown                                                                                       15      12.7         13     7.9          5      7.9          81                8.9
                                                                                                                                                                                      
  CD4+ count, cells/mm^3∗^                                                                                                                                                            
   Median (IQR)                                                                                        225.5   (105, 360)   272    (163, 432)   170    (64, 325)    267.5             (124, 433)
   \<200                                                                                               54      45.8         56     34.2         36     57.1         347               38.3
   200--349                                                                                            32      27.1         46     28.0         11     17.5         229               25.3
   350--499                                                                                            16      13.6         34     20.7         7      11.1         162               17.9
   500+                                                                                                15      12.7         26     15.8         8      12.7         150               16.6
   Missing                                                                                             1       0.8          2      1.2          1      1.6          18                2.0
                                                                                                                                                                                      
  Nadir CD4+ count, cells/mm^3∗†^                                                                                                                                                     
   Median (IQR)                                                                                        99      (34, 213)    126    (40, 247)    55     (20, 206)    105               (32, 247)
   \<50                                                                                                38      32.2         52     31.1         29     46.0         278               30.7
   50--199                                                                                             44      37.3         52     31.7         18     28.6         306               33.8
   200--349                                                                                            24      20.3         38     23.2         12     19.0         184               20.3
   350+                                                                                                9       7.6          20     12.3         4      6.4          101               11.2
   Missing                                                                                             3       2.5          3      1.8          0      0.0          37                4.1
                                                                                                                                                                                      
  HIV RNA viral load, copies/mL\*                                                                                                                                                     
   Median log (IQR)                                                                                    4.6     (3.9, 5.0)   4.2    (3.6, 4.8)   4.5    (3.7, 5.0)   4.3               (3.6, 4.9)
   1,000--9,999                                                                                        35      29.7         65     39.6         23     36.5         368               40.6
   10,000--99,999                                                                                      54      45.8         69     42.1         23     36.5         363               40.1
   ≥100,000                                                                                            29      24.6         30     18.3         17     27.0         175               19.3
                                                                                                                                                                                      
  AIDS\*                                                                                               99      83.9         133    81.1         52     82.5         728               80.4
                                                                                                                                                                                      
  Antiretroviral exposure\*                                                                                                                                                           
   3TC/FTC exposed                                                                                     110     93.2         158    96.3         62     98.4         856               94.5
   NRTI exposed                                                                                        118     100.0        164    100.0        63     100.0        905               99.9
   NNRTI exposed                                                                                       78      66.1         128    78.1         47     74.6         656               72.4
   PI exposed (any)                                                                                    105     89.0         144    87.8         55     87.3         799               88.2
   Ritonavir-boosted PI exposed                                                                        7       5.9          109    66.5         51     81.0         478               52.8
   Mono-dual NRTI exposed                                                                              88      74.6         99     60.4         33     52.4         515               56.8
   Triple-class exposed (TCE)                                                                          55      46.6         94     57.3         32     50.8         496               54.8
   Only cART exposed                                                                                   22      18.6         54     32.9         24     38.1         299               33.0
   Any exposure to all 3 classes of agents (NRTI, NNRTI, and PI)                                       71      60.2         109    66.5         39     61.9         566               62.5
                                                                                                                                                                                      
  ARV exposure duration among those exposed with complete and evaluable ARV history, median months\*   *n*     Median       *n*    Median       *n*    Median       *n*               Median
   3TC/FTC exposed                                                                                     110     22           158    43           62     58           856               37
   NRTI exposed                                                                                        118     44           164    71           63     73           905               62
   NNRTI exposed                                                                                       78      12           128    19           47     23           656               20
   PI exposed (any)                                                                                    105     28           144    51           55     56           799               43
   Ritonoavir-boosted PI exposed                                                                       7       5            108    23           51     36           477               21
   Mono-dual NRTI exposed                                                                              88      19           98     12           31     7            503               13
   Triple-class exposed (TCE)                                                                          38      11           75     46           29     57           394               38
   Only cART exposed                                                                                   11      15           54     36           24     39           299               34
                                                                                                                                                                                      
  Number of ARVs exposed to date, median                                                               118     6            164    8            63     7            906               7
                                                                                                                                                                                      
  Duration of ARV exposure, years, median                                                              118     4.0          164    6.2          63     6.2          906               5.3

^§^ Total number of unique patients during 1999--2008.

\*As of last eligible genotypic test in the year. (For clinical measurements, only values within 6 months prior through 2 weeks after the first eligible genotypic test were considered, the closest one chosen to characterize the patient at time of the GT.).

^†^ *P* value for trend during 1999--2008 was \<0.05.

IQR: interquartile range. GT: genotypic testing; cART: combination antiretroviral therapy; NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; TCE: triple-class exposed; MSM: men who have sex with men; IDU: injection drug use.

###### 

Frequency of resistance mutations among ARV-experienced patients who had genotypic testing performed at viral load \>1,000 copies/mL and while on ARVs, by year, the HIV Outpatient Study, 1999--2008.

  Patient subgroup                                                                         1999            2004             2008            *P* trend\*
  ---------------------------------------------------------------------------------------- --------------- ---------------- --------------- -------------
  Part A. Frequency of any resistance among all tested in the year---by patient subgroup                                                    
                                                                                                                                            
  All patients tested                                                                      88.1  \[118\]   81.7  \[164\]    79.4 \[63\]     0.054
   95% CI                                                                                  (80.9, 93.4)    (74.9, 87.3)     (67.3, 88.5)    
  *By type of ARV experience:*                                                                                                              
  cART only                                                                                68.2  \[22\]    75.9  \[54\]     62.5% \[24\]    0.317
   95% CI                                                                                  (45.1, 86.1)    (62.4, 86.5)     (40.6, 81.2)    
  Mono-dual NRTI                                                                           93.2  \[88\]    86.9  \[99\]     87.9 \[33\]     0.066
   95% CI                                                                                  (85.8, 97.5)    (78.6, 92.8)     (71.8, 96.6)    
  TCE                                                                                      94.5  \[55\]    88.3  \[94\]     93.8 \[32\]     0.426
   95% CI                                                                                  (84.9, 98.9)    (80.0, 94.0)     (79.2, 99.2)    
                                                                                                                                            
  Part B. Frequency of class-specific mutations---among all patients tested in the year                                                     
                                                                                                                                            
  NRTI resistance                                                                          82.2  \[118\]   73.8%  \[164\]   66.7%  \[63\]   0.096
   95% CI                                                                                  (74.1, 88.6)    (66.4, 80.3)     (53.7, 78.0)    
  NNRTI resistance                                                                         46.6  \[118\]   65.2%  \[164\]   55.6%  \[63\]   0.165
   95% CI                                                                                  (37.4, 56.0)    (57.4, 72.5)     (42.5, 68.1)    
  PI resistance                                                                            65.2  \[118\]   50.6%  \[164\]   41.3%  \[63\]   0.018
   95% CI                                                                                  (55.9, 73.8)    (42.7, 58.5)     (29.0, 54.4)    
  Triple-class resistance                                                                  33.9  \[118\]   39.6%  \[164\]   27.0%  \[63\]   0.748
   95% CI                                                                                  (25.4, 43.2)    (32.1, 47.6)     (16.6, 39.6)    
                                                                                                                                            
  Part C. Frequency of class-specific mutations---among tested with prior ARV exposures                                                     
                                                                                                                                            
  NRTI resistance                                                                          82.2  \[118\]   73.8%  \[164\]   66.7%  \[63\]   0.094
   95% CI                                                                                  (74.1, 88.6)    (66.4, 80.3)     (53.7, 78.0)    
  NNRTI resistance                                                                         70.5  \[78\]    75.8%  \[128\]   68.1%  \[47\]   0.384
   95% CI                                                                                  (59.1, 80.3)    (67.4, 82.9)     (52.9, 80.9)    
  PI resistance                                                                            71.4  \[105\]   56.3%  \[144\]   45.5%  \[55\]   0.010
   95% CI                                                                                  (61.8, 79.8)    (47.7, 64.5)     (32.0, 59.4)    
  Triple-class resistance                                                                  65.5  \[55\]    55.3%  \[94\]    40.6%  \[32\]   0.094
   95% CI                                                                                  (51.4, 77.8)    (44.7, 65.6)     (23.7, 59.4)    

\*Linear test for trend using annual estimates for entire period 1999--2008.

Numbers in square brackets indicate denominators (i.e., patients with eligible GT each year).

CI: confidence interval. GT: genotypic testing; cART: combination antiretroviral therapy; NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; TCE: triple-class exposed.
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